260 related articles for article (PubMed ID: 33610731)
21. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
Eastham JA; Grafton W; Martin CM; Williams BJ
J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
[TBL] [Abstract][Full Text] [Related]
22. Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy.
Zhan Q; Yi K; Qi H; Li S; Li X; Wang Q; Wang Y; Liu C; Qiu M; Yuan X; Zhao J; Hou X; Kang C
Theranostics; 2020; 10(17):7889-7905. PubMed ID: 32685027
[No Abstract] [Full Text] [Related]
23. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
[TBL] [Abstract][Full Text] [Related]
24. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Kamerkar S; LeBleu VS; Sugimoto H; Yang S; Ruivo CF; Melo SA; Lee JJ; Kalluri R
Nature; 2017 Jun; 546(7659):498-503. PubMed ID: 28607485
[TBL] [Abstract][Full Text] [Related]
25. The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells.
Yang H; Xiang S; Kazi A; Sebti SM
J Biol Chem; 2020 Mar; 295(10):3055-3063. PubMed ID: 32001619
[TBL] [Abstract][Full Text] [Related]
26. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
27. Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes.
Gautam A; Waldrep JC; Kleinerman ES; Xu B; Fung YK; T'Ang A; Densmore CL
Methods Mol Med; 2003; 75():607-18. PubMed ID: 12407767
[No Abstract] [Full Text] [Related]
28. Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy.
Wallen M; Aqil F; Spencer W; Gupta RC
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514019
[TBL] [Abstract][Full Text] [Related]
29. Efficient targeted pDNA/siRNA delivery with folate-low-molecular-weight polyethyleneimine-modified pullulan as non-viral carrier.
Wang J; Dou B; Bao Y
Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():98-109. PubMed ID: 24268238
[TBL] [Abstract][Full Text] [Related]
30. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.
Alvarez-Erviti L; Seow Y; Yin H; Betts C; Lakhal S; Wood MJ
Nat Biotechnol; 2011 Apr; 29(4):341-5. PubMed ID: 21423189
[TBL] [Abstract][Full Text] [Related]
31. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic silencing of KRAS using systemically delivered siRNAs.
Pecot CV; Wu SY; Bellister S; Filant J; Rupaimoole R; Hisamatsu T; Bhattacharya R; Maharaj A; Azam S; Rodriguez-Aguayo C; Nagaraja AS; Morelli MP; Gharpure KM; Waugh TA; Gonzalez-Villasana V; Zand B; Dalton HJ; Kopetz S; Lopez-Berestein G; Ellis LM; Sood AK
Mol Cancer Ther; 2014 Dec; 13(12):2876-85. PubMed ID: 25281617
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of intracellular reduction-sensitive amphiphilic polyethyleneimine and poly(ε-caprolactone) graft copolymer for on-demand release of doxorubicin and p53 plasmid DNA.
Davoodi P; Srinivasan MP; Wang CH
Acta Biomater; 2016 Jul; 39():79-93. PubMed ID: 27154500
[TBL] [Abstract][Full Text] [Related]
34. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping.
Zheng Z; Li Z; Xu C; Guo B; Guo P
J Control Release; 2019 Oct; 311-312():43-49. PubMed ID: 31446085
[TBL] [Abstract][Full Text] [Related]
35. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse.
Liu Y; Li D; Liu Z; Zhou Y; Chu D; Li X; Jiang X; Hou D; Chen X; Chen Y; Yang Z; Jin L; Jiang W; Tian C; Zhou G; Zen K; Zhang J; Zhang Y; Li J; Zhang CY
Sci Rep; 2015 Dec; 5():17543. PubMed ID: 26633001
[TBL] [Abstract][Full Text] [Related]
36. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
[TBL] [Abstract][Full Text] [Related]
37. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
38. Magnetic field contributes to the cellular uptake for effective therapy with magnetofection using plasmid DNA encoding against Mcam in B16F10 melanoma in vivo.
Prosen L; Hudoklin S; Cemazar M; Stimac M; Lampreht Tratar U; Ota M; Scancar J; Romih R; Sersa G
Nanomedicine (Lond); 2016 Mar; 11(6):627-41. PubMed ID: 27021639
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous regulation of apoptotic gene silencing and angiogenic gene expression for myocardial infarction therapy: Single-carrier delivery of SHP-1 siRNA and VEGF-expressing pDNA.
Kim D; Ku SH; Kim H; Jeong JH; Lee M; Kwon IC; Choi D; Kim SH
J Control Release; 2016 Dec; 243():182-194. PubMed ID: 27765623
[TBL] [Abstract][Full Text] [Related]
40. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
